Literature DB >> 2437978

The comparative pharmacokinetics of 3H-dihydrostreptomycin in solution and liposomal form in normal and Mycobacterium tuberculosis infected mice.

G A Ladigina, M A Vladimirsky.   

Abstract

In intact and tuberculous mice a comparative pharmacokinetics of 3H-dihydrostreptomycin (DHS) encapsulated into the liposomes (LE) prepared from egg lecithin and soluble form of DHS (SOL) after their intravenous administration has been studied. The values of the total area under the serum concentration--time curve of DHS (AUC 0----infinity), administered in the LE form was 8.8 times higher in normal and 5.9 times higher in mice with advanced tuberculosis than in mice treated with soluble form of DHS (SOL). AUC 0----infinity values in spleen and liver were 2.2 and 4.5 times higher, respectively, in use of LE form, where as AUC 0----infinity values in lungs and kidneys were independent from the drug form of DHS in normal mice. DHS levels in lungs of tuberculous mice were 3 times higher 3 hours after administration of LE in comparison with those after SOL DHS. AUC 0----infinity values in spleen and liver of tuberculous mice were 9.2 and 7.3 times higher, respectively, in comparison with those after SOL DHS. AUC 0----infinity values in kidneys of tuberculous mice didn't differ significantly independently from the use of one or another form of the drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2437978

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  M H Cynamon; C E Swenson; G S Palmer; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 2.  Parenteral aminoglycoside therapy. Selection, administration and monitoring.

Authors:  C R Kumana; K Y Yuen
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

3.  Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis.

Authors:  R C Weiss; N R Cox; M L Martinez
Journal:  Res Vet Sci       Date:  1993-09       Impact factor: 2.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.